XORTX Therapeutics Inc. XRTX
XORTX Therapeutics Inc. (Nasdaq: XRTX) is a cardio-renal-metabolic drug developer. Its lead program, XRx-026 (XORLO, proprietary oxypurinol formulation), is in Phase 2 for Gout (hyperuricemia-associated). Its next catalyst on record is XRx-026: File Clinical Trial Application with Health Canada for XRX-OXY-102 (part one in Canada) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XRx-026 — File Clinical Trial Application with Health Canada for XRX-OXY-102 (part one in Canada) (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XRx-026 (XORLO) - planned two-part XRX-OXY-102 bridging PK / therapeutic-equivalence study; 505(b)(2) pathway | Gout | small molecule | Phase 2 |
| XRx-008 (oxypurinol) - XRX-OXY-101 PK bridging study reported; Phase 3 registration trial not yet started | Autosomal dominant polycystic kidney disease (ADPKD) | small molecule | Phase 2 |
| XRx-101 (IV uric acid lowering plus oral XOI) | Acute kidney injury with respiratory virus infection / sepsis | small molecule | Phase 2 |
| VB4-P5 (acquired from Vectus) | Renal interstitial fibrosis / kidney disease | small molecule | Pre-clinical |
| XRx-225 | Type 2 diabetic nephropathy | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.